SPOT-mRNA03 Gene Therapy for Duchenne Muscular Dystrophy Begins Early Phase 1 Clinical Trial
The early phase 1 study (NCT07188012) of SPOT-mRNA03 gene therapy for Duchenne Muscular Dystrophy (DMD) developed by Shanghai Siponuoyin Biotechnology is a pilot study...
Solid Biosciences Initiates Phase 3 Clinical Trial of SGT-003 Gene Therapy (IMPACT DUCHENNE) in Ambulant Males
The phase 3 study (NCT07160634) of the SGT-003 gene therapy developed by Solid Biosciences is expected to begin in October 2025 and be completed...
GNR-097: Duchenne Gene Therapy Phase 1/2 Study Started by Generium
Generium is a Russian innovative biotechnology company has received approval to conduct a clinical trial of GNR-097 gene therapy drug for the treatment of...
ITF Therapeutics Launching A Study to Evaluate the Real-World Experience of Duvyzat (Givinostat) in Patients With Duchenne Muscular Dystrophy
The purpose of this prospective observational study (NCT07127978) is to assess the safety, tolerability, and functional results of DMD patients who are starting oral...
Revidia Therapeutics MSI-1436 Holds Promise for Treating Heart Failure in DMD Patients
Human babies may indeed repair myocardial damage and fully recover normal cardiac function following a severe myocardial infarction, despite the seemingly unrealistic idea that...